Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028327 | 1.00 | KMT2A (0.34) | KMT2AHTR2AHTR2CKCNH2MEN1 | |
| SCHEMBL4772529 | 0.87 | KCNH2 (0.43) | KMT2AKCNH2MEN1KDM4EALDH1A1 | |
| SCHEMBL4780151 | 0.87 | KCNH2 (0.43) | KMT2AKCNH2MEN1KDM4EALDH1A1 | |
| SCHEMBL4024481 | 0.79 | KIF11 (0.34) | KMT2AMEN1ALDH1A1RORC | |
| SCHEMBL4026044 | 0.79 | KIF11 (0.34) | KMT2AMEN1ALDH1A1RORC | |
| SCHEMBL4894830 | 0.78 | POLB (0.44) | KMT2AKCNH2MEN1KDM4EALDH1A1 | |
| SCHEMBL4795657 | 0.78 | POLB (0.44) | KMT2AKCNH2MEN1KDM4EALDH1A1 | |
| SCHEMBL4894834 | 0.78 | POLB (0.44) | KMT2AKCNH2MEN1KDM4EALDH1A1 | |
| SCHEMBL4022116 | 0.78 | CYP2C9 (0.41) | KMT2AHTR2AKCNH2MEN1ALDH1A1 | |
| SCHEMBL4775780 | 0.77 | KCNH2 (0.40) | KMT2AKCNH2ALDH1A1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KMT2A 2820/4885HTR2A 4141/4885HTR2C 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.